Role of miR-9 and miR-223 in Ovarian Cancer
Author Information
Author(s): Laios Alexandros, O'Toole Sharon, Flavin Richard, Martin Cara, Kelly Lynn, Ring Martina, Finn Stephen P, Barrett Ciara, Loda Massimo, Gleeson Noreen, D'Arcy Tom, McGuinness Eamonn, Sheils Orla, Sheppard Brian, O' Leary John
Primary Institution: Trinity College Dublin
Hypothesis
This study investigates the expression levels of miRNAs in recurrent ovarian cancer and their potential as biomarkers.
Conclusion
The study identifies miR-9 as a potential tumor suppressor and miR-223 as a significant biomarker in recurrent ovarian cancer.
Supporting Evidence
- Distinct miRNA expression profiles were found between primary and recurrent ovarian cancers.
- miR-223 was significantly upregulated in recurrent tumors.
- miR-9 was significantly downregulated in recurrent tumors.
- The study provides evidence that miR-9 may act as a tumor suppressor.
Takeaway
Researchers found that two tiny molecules called miR-9 and miR-223 behave differently in recurring ovarian cancer, which might help doctors understand and treat the disease better.
Methodology
Real-time RT-PCR was used to analyze miRNA expression in fresh frozen and FFPE ovarian tumor samples.
Potential Biases
Potential bias in sample selection and analysis methods.
Limitations
The study is limited by the small sample size and the focus on specific miRNAs.
Participant Demographics
Patients included in the study had a mean age of 63.3 years for primary and 53.3 years for recurrent cases.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website